Savara (NASDAQ:SVRA) Upgraded at Wall Street Zen

Savara (NASDAQ:SVRA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Savara in a report on Monday, March 16th. Oppenheimer initiated coverage on shares of Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. Finally, William Blair set a $10.00 target price on shares of Savara in a report on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $10.14.

Savara Price Performance

Savara stock opened at $5.26 on Friday. Savara has a 12 month low of $1.98 and a 12 month high of $7.01. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The business’s 50 day simple moving average is $5.29 and its 200 day simple moving average is $5.60. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -9.39 and a beta of 0.26.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Sell-side analysts forecast that Savara will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SVRA. Rhumbline Advisers grew its position in Savara by 10.8% in the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock worth $388,000 after acquiring an additional 16,634 shares in the last quarter. Prudential Financial Inc. purchased a new position in Savara in the second quarter worth $30,000. XTX Topco Ltd purchased a new position in Savara in the second quarter worth $201,000. Invesco Ltd. grew its position in Savara by 35.4% in the second quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock worth $276,000 after acquiring an additional 31,633 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Savara by 14.2% in the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after acquiring an additional 6,449 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.